Back

Safety profile of a ventricular leadless pacemaker. Data from 1265 patients in the France LEADLESS study.

12 April 2026 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Leadless pacing (1) Antibradycardia Pacing EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Pascal Defaye

CHU Grenoble, Grenoble (France)

6 More presentations in this session

Presentation thumbnail
Safety of leadless pacemaker implantation in centers with and without on-site cardiac surgery: a real-world multicenter experience
Doctor G. Manzo (Nocera Inferiore, IT)
Abstract Slides Video
Presentation thumbnail
Development and validation of a risk score for predicting the difficulty in leadless pacemaker implantation
Doctor N. Ishizue (Sagamihara, JP)
Abstract Slides Video
Presentation thumbnail
Initial results of the new screw-in leadless pacemaker Avier AR
Doctor M. Nagashima (Kitakyushu, JP)
Abstract Slides Video
Presentation thumbnail
Leadless pacemaker implantation after transcatheter tricuspid valve replacement: first experiences and safety of the jugular approach
Doctor C. auf der Heiden (Duesseldorf, DE)
Abstract Slides Video
Presentation thumbnail
Learning curve in leadless pacemaker implantation: impact of center experience on procedure and fluoroscopy times in the france LEADLESS registry
Professor E. Marijon (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Leadless pacing (1)

The Event

Event poster

EHRA 2026

12 April 2026 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Preliminary results of the France LEADLESS study. A safety and effectiveness monitoring of a new ventricular leadless pacemaker.
thumbnail
Congress Presentation
Long term outcomes of dual chamber leadless pacemaker insights from European patients data
thumbnail
Congress Presentation
12 years of leadless pacing: what did we learn?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources